251
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response of relapsed central nervous system hairy cell leukemia to vemurafenib

, , , , &
Pages 2952-2954 | Received 06 Mar 2016, Accepted 08 Apr 2016, Published online: 27 Apr 2016

References

  • Dores GM, Matsuno RK, Weisenburger DD, et al. Hairy cell leukaemia: a heterogeneous disease? Br J Haematol. 2008;142:45–51.
  • Chandana SR, Kotecha R, Al-Janadi A, et al. Rare case of hairy cell leukemia with brain parenchymal involvement: a diagnostic dilemma. J Clin Oncol. 2013;31:e186–e188.
  • Knecht H, Budmiger H, Groscurth P, et al. Central nervous system involvement in hairy cell leukemia. Klin Wochenschr. 1985;63:423–427.
  • Le Bezu M, Pinaudeau Y, Poirier J, et al. Involvement of the nervous system in hairy-cell leukemia. Arch Neurol. 1986;43:432.
  • Kimmel DW, Hermann RC Jr, O’Neill BP. Neurologic complications of hairy cell leukemia. Arch Neurol. 1984;41:202–203.
  • Wolfe DW, Scopelliti JA, Boselli BD. Leukemic meningitis in a patient with hairy cell leukemia. A case report. Cancer. 1984;54:1085–1087.
  • Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–2315.
  • Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85
  • Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943–3949.
  • Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;5:2.
  • Badalian-Very G, Vergilio JA, Degar BA, et al. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012;156:163–172.
  • Bailleux C, Robert G, Ginet C, et al. Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. Oncoscience. 2015;2:44–49.
  • Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98:e20–e22.
  • Jain P, Polliack A, Ravandi F. Novel therapeutic options for relapsed hairy cell leukemia. Leuk Lymphoma. 2015;2:2264–2272.
  • Kolar GR, Miller-Thomas MM, Schmidt RE, et al. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol. 2013;31:e40–e43.
  • Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54:1235–1239.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.